Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 7;12(3):e027572.
doi: 10.1161/JAHA.122.027572. Epub 2023 Jan 25.

Intracranial Hemorrhage Rate and Lesion Burden in Patients With Familial Cerebral Cavernous Malformation

Collaborators, Affiliations

Intracranial Hemorrhage Rate and Lesion Burden in Patients With Familial Cerebral Cavernous Malformation

Shantel Weinsheimer et al. J Am Heart Assoc. .

Abstract

Background Familial cerebral cavernous alformation (CCM) is an autosomal dominant disease caused by mutations in KRIT1, CCM2, or PDCD10. Cases typically present with multiple lesions, strong family history, and neurological symptoms, including seizures, headaches, or other deficits. Intracranial hemorrhage (ICH) is a severe manifestation of CCM, which can lead to death or long-term neurological deficits. Few studies have reported ICH rates and risk factors in familial CCM. We report ICH rates and assess whether CCM lesion burden, a disease severity marker, is associated with risk of symptomatic ICH during follow-up in a well-characterized cohort of familial CCM cases. Methods and Results We studied 386 patients with familial CCM with follow-up data enrolled in the Brain Vascular Malformation Consortium CCM Project. We estimated symptomatic ICH rates overall and stratified by history of ICH before enrollment. CCM lesion burden (total lesion count and large lesion size) assessed at baseline enrollment was tested for association with increased risk of subsequent ICH during follow-up using Cox regression models adjusted for history of ICH before enrollment, age, sex, and family structure and stratified on recruitment site. The symptomatic ICH rate for familial CCM cases was 2.8 per 100 patient-years (95% CI, 1.9-4.1). Those with ICH before enrollment had a follow-up ICH rate of 4.5 per 100 patient-years (95% CI, 2.6-8.1) compared with 2.0 per 100 patient-years (95% CI, 1.3-3.5) in those without (P=0.042). Total lesion count was associated with increased risk of ICH during follow-up (hazard ratio [HR], 1.37 per doubling of total lesion count [95% CI, 1.10-1.71], P=0.006). The symptomatic ICH rate for familial CCM cases was 2.8 per 100 patient-years (95% CI, 1.9-4.1). Those with ICH before enrollment had a follow-up ICH rate of 4.5 per 100 patient-years (95% CI, 2.6-8.1) compared with 2.0 per 100 patient-years (95% CI, 1.3-3.5) in those without (P=0.042). Total lesion count was associated with increased risk of ICH during follow-up (hazard ratio [HR], 1.37 per doubling of total lesion count [95% CI, 1.10-1.71], P=0.006). Conclusions Patients with familial CCM with prior history of an ICH event are at higher risk for rehemorrhage during follow-up. In addition, total CCM lesion burden is significantly associated with increased risk of subsequent symptomatic ICH; hence lesion burden may be an important predictor of patient outcome and aid patient risk stratification.

Keywords: cerebral cavernous malformation; familial; hemorrhage; risk factor.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Kaplan–Meier survival curves of hemorrhage during follow‐up in a cohort of patients with familial cerebral cavernous malformation enrolled between 2010 and 2019.
Number in parentheses is number of events that occur within each interval. Numbers at 2, 4, and 6 years indicate individuals still at risk for intracranial hemorrhage (ie, not lost to follow‐up). Figure is truncated at 6 years (includes most data). Hem indicates hemorrhage.

References

    1. Labauge P, Brunereau L, Laberge S, Houtteville JP. Prospective follow‐up of 33 asymptomatic patients with familial cerebral cavernous malformations. Neurology. 2001;57:1825–1828. doi: 10.1212/WNL.57.10.1825 - DOI - PubMed
    1. Zabramski JM, Wascher TM, Spetzler RF, Johnson B, Golfinos J, Drayer BP, Brown B, Rigamonti D, Brown G. The natural history of familial cavernous malformations: results of an ongoing study. J Neurosurg. 1994;80:422–432. doi: 10.3171/jns.1994.80.3.0422 - DOI - PubMed
    1. Al‐Shahi Salman R, Hall JM, Horne MA, Moultrie F, Josephson CB, Bhattacharya JJ, Counsell CE, Murray GD, Papanastassiou V, Ritchie V, et al. Untreated clinical course of cerebral cavernous malformations: a prospective, population‐based cohort study. Lancet Neurol. 2012;11:217–224. doi: 10.1016/S1474-4422(12)70004-2 - DOI - PMC - PubMed
    1. Morris Z, Whiteley WN, Longstreth WT Jr, Weber F, Lee YC, Tsushima Y, Alphs H, Ladd SC, Warlow C, Wardlaw JM, et al. Incidental findings on brain magnetic resonance imaging: systematic review and meta‐analysis. BMJ. 2009;339:b3016. doi: 10.1136/bmj.b3016 - DOI - PMC - PubMed
    1. Moore SA, Brown RD Jr, Christianson TJ, Flemming KD. Long‐term natural history of incidentally discovered cavernous malformations in a single‐center cohort. J Neurosurg. 2014;120:1188–1192. doi: 10.3171/2014.1.JNS131619 - DOI - PubMed

Publication types

MeSH terms

Supplementary concepts